Pharmacology and Treatment
A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgarisKaufmann R.a · Bibby A.J.b · Bissonnette R.e · Cambazard F.f · Chu A.C.c · Decroix J.g · Douglas W.S.d · Lowson D.b · Mascaro J.M.h · Murphy G.M.i · Stymne B.j
aGoethe-Universität, Frankfurt, Germany; bLeo Pharmaceuticals, Princes Risborough, cHammersmith Hospital, London, and dMonklands Hospital, Airdrie, UK; eInnovaderm Research Inc., Montreal, Canada; fHôpital Nord, St-Etienne, France; gMouscron, Belgium; hHospital Clinic i Provincial, Barcelona, Spain; iBeaumont Hospital, Dublin, Ireland; jRegionsjukhuset RSÖ, Örebro, Sweden
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Topical corticosteroids and calcipotriol have been used separately for many years to treat psoriasis. A new combination ointment has been formulated, which contains both calcipotriol and the corticosteroid betamethasone dipropionate. Objective: To compare the combination ointment with betamethasone dipropionate ointment, calcipotriol ointment and ointment vehicle in patients with psoriasis vulgaris. Methods: 1,603 patients were randomised to one of the 4 double-blind treatments used once daily for 4 weeks. Results: Themean percentage change in the PASI at the end of treatment was –71.3 (combination), –57.2 (betamethasone), –46.1 (calcipotriol) and –22.7 (vehicle). The mean difference of combination minus betamethasone was –14.2 (95% CI: –17.6 to –10.8, p < 0.001), of combination minus calcipotriol –25.3 (95% CI: –28.7 to –21.9, p < 0.001) and of combination minus vehicle –48.3 (95% CI: –53.2 to –43.4, p < 0.001). 6.0% of patients (combination) reported local adverse reactions compared to 4.9% (betamethasone), 11.4% (calcipotriol) and 13.6% (vehicle). Conclusion: Calcipotriol/betamethasone dipropionate combination ointment used once daily is well tolerated and more effective than either active constituent used alone.
© 2002 S. Karger AG, Basel
- Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995;332:581–588.
- Nevitt GJ, Hutchinson PE: Psoriasis in the community: Prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533–537.
- Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236–244.
- Berth-Jones J, Chu AC, Dodd WAH, Ganpule M, Griffiths W, Haydey R, Klaber M, Murray S, Rogers S, Jurgensen H: A multi-centre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266–271.
Ellis JP, Griffiths WAD, Klaber MR: Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short-contact dithranol. Eur J Clin Res 1995;7:247–257.
- Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerkhof PCM, Larko O, Nieboer C, Roed-Petersen J, Strand A, Tikjøb G: Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193–196.
- Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, Henderson C, Holden C, Maddin S, Ortonne J, Young M: Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736–743.
- Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, Ruzicka T, van de Kerkhof P: Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: Tolerability and efficacy. Br J Dermatol 1998;139:649–654.
- Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, Moore J: A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268–269.
- Ruzicka T, Lorenz B: Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the topical therapy of psoriasis vulgaris: A multicentre, double-blind, randomized study. Br J Dermatol 1998;138:254–258.
- Patel B, Siskin S, Krazmien R, Lebwohl M: Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38:1010–1011.
- Roberts DT: Comparison of fluticasone propionate ointment, 0.005%, and betamethasone 17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis 1996;57:27–31.
- Shupack JL, Jondreau L, Kenny C, Stiller MJ: Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate–severe plaque-type psoriasis. Dermatology 1993;186:129–132.
Chuang TY, Samson CR: Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone diacetate ointment for psoriasis – A multicentre, randomized, double-blinded study. J Dermatol Treat 1991;2:63–66.
Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PCM, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A: Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol, in press.
- Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ: A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131–135.
- Gollnick H, Menke T: Current experience with tacalcitol ointment in the treatment of psoriasis. Curr Med Res Opin 1998;14:213–218.
- Lagos BR, Maibach HI: Frequency of application of topical corticosteroids: An overview. Br J Dermatol 1998;139:763–766.
- Woodford R, Haigh JM, Barry BW: Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications. Dermatologica 1983;166:136–140.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.